MRNA
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Moderna, Inc. - Common Stock (MRNA) [ST]
www.modernatx.com ↗▼ 1.08%
prev close
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Congressional Trades
3
All tracked trades
Members Trading
3
Unique members
Net Activity
-3
0 buys · 3 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-04-08 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 329d ago | — | |
| 2025-01-15 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 414d ago | — | |
| 2024-02-01 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 756d ago | — |
2025-04-08
Rob Bresnahan
MRNA
Amount
$1,001 - $15,000
Filed
329d ago
2025-01-15
Julie Johnson
MRNA
Amount
$1,001 - $15,000
Filed
414d ago
2024-02-01
Josh Gottheimer
MRNA
Amount
$1,001 - $15,000
Filed
756d ago
Recent News
Powered by Polygon.io
Oil Tumbles, Nasdaq 100 Jumps 3% As Iran Says It's Ready To Halt Hostilities: 10 Stocks Moving
Moderna Stock is Soaring. Is It Too Late to Buy?
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?
Trade Timeline
Congressional activity, newest first
Rob Bresnahan
2025-04-08 · Sale
$1,001 - $15,000
Julie Johnson
2025-01-15 · Sale
$1,001 - $15,000
Josh Gottheimer
2024-02-01 · Sale
$1,001 - $15,000